Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint TherapyKathrin Renner, Marina Kreutz, Christina Bruß et al.|Cell Reports|2019Cited by 297
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark Selby, Alan J. Korman|PLoS ONE|2016Cited by 228
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetZachary T. Freeman, Charles G. Drake, Christina M. Kochel et al.|Journal of Clinical Investigation|2020Cited by 133